Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Nick

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Molecular Cancer Therapeutics|April 8, 2010
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancerWilliam M Merritt, Alpa M Nick, Amy R Carroll, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 19, 2013
Impact of cardiovascular comorbidity on ovarian cancer mortalityEileen H Shinn, Daniel J Lenihan, Diana L Urbauer, et al.
Gynecologic Oncology|July 30, 2019
Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expressionLois M Ramondetta, Wei Hu, Premal H Thaker, et al.
Cancer Biology & Therapy|December 17, 2009
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma modelsChunhua Lu, Mian M K Shahzad, Myrthala Moreno-Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2014
Differential platelet levels affect response to taxane-based therapy in ovarian cancerJustin Bottsford-Miller, Hyun-Jin Choi, Heather J Dalton, et al.
Cancer Biology & Therapy|April 24, 2014
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancerRebecca L Stone, Keith A Baggerly, Guillermo N Armaiz-Pena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2014
Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancerSusan L Tucker, Kshipra Gharpure, Shelley M Herbrich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2010
Targeted gene silencing using RGD-labeled chitosan nanoparticlesHee Dong Han, Lingegowda S Mangala, Jeong Won Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2010
EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinomaJeong-Won Lee, Rebecca L Stone, Sun Joo Lee, et al.
International Journal of Cancer|December 6, 2008
Functional significance of VEGFR-2 on ovarian cancer cellsWhitney A Spannuth, Alpa M Nick, Nicholas B Jennings, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Molecular Cancer Therapeutics|April 8, 2010
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancerWilliam M Merritt, Alpa M Nick, Amy R Carroll, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 19, 2013
Impact of cardiovascular comorbidity on ovarian cancer mortalityEileen H Shinn, Daniel J Lenihan, Diana L Urbauer, et al.
Gynecologic Oncology|July 30, 2019
Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expressionLois M Ramondetta, Wei Hu, Premal H Thaker, et al.
Cancer Biology & Therapy|December 17, 2009
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma modelsChunhua Lu, Mian M K Shahzad, Myrthala Moreno-Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2014
Differential platelet levels affect response to taxane-based therapy in ovarian cancerJustin Bottsford-Miller, Hyun-Jin Choi, Heather J Dalton, et al.
Cancer Biology & Therapy|April 24, 2014
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancerRebecca L Stone, Keith A Baggerly, Guillermo N Armaiz-Pena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2014
Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancerSusan L Tucker, Kshipra Gharpure, Shelley M Herbrich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2010
Targeted gene silencing using RGD-labeled chitosan nanoparticlesHee Dong Han, Lingegowda S Mangala, Jeong Won Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2010
EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinomaJeong-Won Lee, Rebecca L Stone, Sun Joo Lee, et al.
International Journal of Cancer|December 6, 2008
Functional significance of VEGFR-2 on ovarian cancer cellsWhitney A Spannuth, Alpa M Nick, Nicholas B Jennings, et al.
Pageof 16